论文部分内容阅读
本文观察了脑血栓病人使用蝮蛇抗栓酶─Ⅲ号药治疗前后机体红细胞C3b受体（RBC─C3bR）及红细胞免疫复合物受体（RBC-ICR）的变化情况，结果显示脑血栓病人RBC-C3bR及RBC─ICR均低于正常对照（P＜0．001），而经使用蝮蛇抗栓酶─Ⅲ号药治疗后，二者无明显上升，其结果与治疗前或与正常对照比较均有明显差异（P＜0．001）。提示脑血栓病人存在着红细胞免疫功能的严重低下，这样有利于脑血栓的形成及进一步发展，同时也说明蝮蛇抗栓酶─Ⅲ号药在治疗脑血栓病方面，可明显提高其红细胞免疫功能，从而降低红细胞的积聚，提高红细胞清除免疫复合物的功能，继之使血栓得到溶解，病情缓解。
In this paper, we observed the changes of RBC-C3bR and RBC-ICR in patients with cerebral thrombosis before and after treatment with viper’s antithrombin-III drug. The results showed that RBC -C3bR and RBC ─ ICR were lower than the normal control (P <0.001), while the use of viper antithrombin ─ Ⅲ drug treatment, the two did not significantly increase the results compared with before treatment or compared with the normal control There were significant differences (P <0.001). Suggesting that patients with cerebral thrombosis there is a serious low erythrocyte immune function, which is conducive to the formation and further development of cerebral thrombosis, but also shows viper antithrombotic enzyme Ⅲ in the treatment of cerebral thrombosis, can significantly improve the immune function of red blood cells , Thereby reducing the accumulation of red blood cells and improve the function of erythrocyte clearance of immune complexes, followed by the thrombosis was dissolved, the disease eased.